HUE027554T2 - A DOTAP-klorid (2R)-enantiomerje - Google Patents

A DOTAP-klorid (2R)-enantiomerje Download PDF

Info

Publication number
HUE027554T2
HUE027554T2 HUE05802304A HUE05802304A HUE027554T2 HU E027554 T2 HUE027554 T2 HU E027554T2 HU E05802304 A HUE05802304 A HU E05802304A HU E05802304 A HUE05802304 A HU E05802304A HU E027554 T2 HUE027554 T2 HU E027554T2
Authority
HU
Hungary
Prior art keywords
amely amely
chloride
dotap
liposomes
preparation
Prior art date
Application number
HUE05802304A
Other languages
English (en)
Inventor
Michael Platscher
Alfred Hedinger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUE027554T2 publication Critical patent/HUE027554T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (2)

  1. Sxsst>adalsó îg«»ypô»tôk I. EssoteRádkitag feats (SR)-! (2'ásotco£ioxi-3-trfmeiíIamnmoiíím~propás>ídöHd [(2R)-IXJTAP~ kicsid}].
  2. 3. Gyi>gysæœé$zsâ kèæîimàey» amely eosnfemenasfag tiszta (^R)'DÖTAF-kiorídbt íartsíam gyógyszerészeíöeg aktív vegySietek&d, a^vánsokicalvagy oldószerrel egyöít. 4. A3, Igéaypeot szedsîi gyógyszerészeti készítmény, amely eaantioinedaiiag tiszte, (2R)-DÖTAF-fdorídot tartalmaz, azza f jellemezve, hogy sz alkalmazott gyégyszsrészetílegaktív vágyóiéi a kővetkező csöpoítból választóit aktív fegyüiefc psphdek, mddeoddok,, vakoltaik és OítoaKtaííkas szerek. 5. A 3. ^2Β|κ130®54ΐ^ fctohfet toÍám?, hfeml Jellemezve, hogy tartalmaz líposaemákst, Hgoídeke&eí, íssöörésíKeéskéketyagy mlkïoeroaiîdSkat,
HUE05802304A 2004-11-26 2005-11-07 A DOTAP-klorid (2R)-enantiomerje HUE027554T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid

Publications (1)

Publication Number Publication Date
HUE027554T2 true HUE027554T2 (hu) 2016-10-28

Family

ID=35789283

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE05802304A HUE027554T2 (hu) 2004-11-26 2005-11-07 A DOTAP-klorid (2R)-enantiomerje

Country Status (21)

Country Link
US (2) US8853283B2 (hu)
EP (1) EP1814843B1 (hu)
JP (1) JP4880612B2 (hu)
KR (1) KR101249370B1 (hu)
CN (2) CN101065350A (hu)
AU (1) AU2005309107B2 (hu)
BR (2) BRPI0518489B8 (hu)
CA (1) CA2589218C (hu)
DE (1) DE102004057303A1 (hu)
ES (1) ES2545906T3 (hu)
HK (1) HK1178143A1 (hu)
HU (1) HUE027554T2 (hu)
IL (1) IL183324A (hu)
MX (1) MX2007006128A (hu)
NO (1) NO338885B1 (hu)
NZ (2) NZ582382A (hu)
PL (1) PL1814843T3 (hu)
PT (1) PT1814843E (hu)
RU (1) RU2463291C2 (hu)
WO (1) WO2006056312A1 (hu)
ZA (1) ZA200705169B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
RU2530555C2 (ru) * 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
SG194957A1 (en) * 2011-05-20 2013-12-30 Merck Patent Gmbh Stable crystal modifications of dotap chloride
US10738355B2 (en) 2011-05-24 2020-08-11 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh Individualized vaccines for cancer
PL2755680T3 (pl) * 2011-09-12 2019-03-29 Pds Biotechnology Corporation Preparaty szczepionkowe w postaci cząstek
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
EP3417874A1 (en) 2012-11-28 2018-12-26 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
PL199201B1 (pl) * 1996-05-08 2008-08-29 Nika Health Products Ltd Pęcherzyk lipidowy, sposób wytwarzania pęcherzyka lipidowego oraz zastosowanie pęcherzyka lipidowego
ES2305157T3 (es) * 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) * 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) * 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
DE102004057303A1 (de) 2006-06-01
IL183324A (en) 2013-10-31
AU2005309107B2 (en) 2011-07-21
IL183324A0 (en) 2007-09-20
CA2589218A1 (en) 2006-06-01
JP4880612B2 (ja) 2012-02-22
KR101249370B1 (ko) 2013-04-01
EP1814843B1 (de) 2015-06-24
NZ582382A (en) 2010-08-27
NZ556060A (en) 2010-03-26
BRPI0518489B1 (pt) 2020-03-31
BR122019018186B1 (pt) 2021-03-09
ZA200705169B (en) 2008-08-27
CN102796016A (zh) 2012-11-28
PL1814843T3 (pl) 2015-11-30
CN102796016B (zh) 2015-09-02
US20080014254A1 (en) 2008-01-17
EP1814843A1 (de) 2007-08-08
MX2007006128A (es) 2007-07-13
JP2008521757A (ja) 2008-06-26
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
KR20070084501A (ko) 2007-08-24
BR122019018186B8 (pt) 2021-07-27
US9457087B2 (en) 2016-10-04
AU2005309107A1 (en) 2006-06-01
US8853283B2 (en) 2014-10-07
BRPI0518489A2 (pt) 2008-11-25
ES2545906T3 (es) 2015-09-16
BRPI0518489B8 (pt) 2021-05-25
WO2006056312A1 (de) 2006-06-01
CN101065350A (zh) 2007-10-31
US20140370081A1 (en) 2014-12-18
RU2007123673A (ru) 2009-01-10
PT1814843E (pt) 2015-10-13
CA2589218C (en) 2013-12-17
HK1178143A1 (zh) 2013-09-06
NO20073286L (no) 2007-06-25

Similar Documents

Publication Publication Date Title
HUE027554T2 (hu) A DOTAP-klorid (2R)-enantiomerje
JP2018203776A (ja) Ｄｏｔａｐ塩化物の安定な結晶改質物
US8513446B2 (en) Stable crystal modifications of DOPC
NZ619175B2 (en) Stable crystal modifications of dotap chloride